Comparative Pharmacology
Head-to-head clinical analysis: BELBUCA versus DILAUDID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELBUCA versus DILAUDID.
BELBUCA vs DILAUDID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Partial mu-opioid receptor agonist; produces analgesia by binding to mu-opioid receptors in the CNS, with ceiling effect on respiratory depression.
Dilaudid (hydromorphone) is a full opioid agonist with high affinity for mu-opioid receptors, producing analgesia by mimicking endogenous endorphins and enkephalins. It also activates kappa and delta opioid receptors to a lesser extent.
Apply one buccal film to inner cheek every 12 hours. Initiate at 75 mcg once daily or every 12 hours for opioid-experienced patients; titrate in increments of 75-150 mcg every 4 days. Maximum dose: 900 mcg every 12 hours.
Initial: 2-4 mg orally every 4-6 hours as needed; or 1-2 mg intramuscularly, subcutaneously, or intravenously every 4-6 hours as needed.
None Documented
None Documented
Terminal elimination half-life of buprenorphine is approximately 24-42 hours, allowing for twice-weekly dosing of BELBUCA.
2.5-3.5 hours (terminal); prolonged in hepatic/renal impairment
Primarily renal (70-80% as metabolites, ~15% as unchanged buprenorphine); biliary/fecal excretion accounts for ~10-20%.
Primarily renal (90% as hydromorphone-3-glucuronide and parent drug); <1% biliary/fecal
Category C
Category C
Opioid Analgesic
Opioid Analgesic